Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ADXN NASDAQ:ITRM NASDAQ:OKUR NASDAQ:SNTI On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeADXNAddex Therapeutics$9.78-9.9%$8.37$6.51▼$12.05$11.50M1.3861,537 shs8,369 shsITRMIterum Therapeutics$0.68+1.4%$0.76$0.61▼$3.02$31.61M3.04621,213 shs392,569 shsOKUROnKure Therapeutics$2.48+3.8%$2.47$1.70▼$20.00$32.34M0.4350,534 shs17,770 shsSNTISenti Biosciences$1.39+1.5%$1.63$1.26▼$16.94$35.84M2.06119,838 shs53,666 shs10 Best Stocks to Own: Fall 2025Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Fall 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceADXNAddex Therapeutics-9.91%+11.33%+20.60%+10.09%+1.93%ITRMIterum Therapeutics+1.42%-4.13%-18.20%-31.35%-37.65%OKUROnKure Therapeutics+3.77%+1.64%-9.49%+4.64%+247,999,900.00%SNTISenti Biosciences+1.46%+0.72%-13.13%-34.74%-55.02%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeADXNAddex Therapeutics$9.78-9.9%$8.37$6.51▼$12.05$11.50M1.3861,537 shs8,369 shsITRMIterum Therapeutics$0.68+1.4%$0.76$0.61▼$3.02$31.61M3.04621,213 shs392,569 shsOKUROnKure Therapeutics$2.48+3.8%$2.47$1.70▼$20.00$32.34M0.4350,534 shs17,770 shsSNTISenti Biosciences$1.39+1.5%$1.63$1.26▼$16.94$35.84M2.06119,838 shs53,666 shs10 Best Stocks to Own: Fall 2025Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Fall 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceADXNAddex Therapeutics-9.91%+11.33%+20.60%+10.09%+1.93%ITRMIterum Therapeutics+1.42%-4.13%-18.20%-31.35%-37.65%OKUROnKure Therapeutics+3.77%+1.64%-9.49%+4.64%+247,999,900.00%SNTISenti Biosciences+1.46%+0.72%-13.13%-34.74%-55.02%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceADXNAddex Therapeutics 3.00Buy$30.00206.91% UpsideITRMIterum Therapeutics 3.00Buy$9.001,224.31% UpsideOKUROnKure Therapeutics 3.14Buy$32.331,203.76% UpsideSNTISenti Biosciences 3.00Buy$8.50511.51% UpsideCurrent Analyst Ratings BreakdownLatest ADXN, OKUR, SNTI, and ITRM Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails8/26/2025OKUROnKure TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$34.008/13/2025OKUROnKure TherapeuticsZacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeStrong-Buy ➝ Hold8/8/2025SNTISenti BiosciencesChardan CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$12.00(Data available from 9/19/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookADXNAddex Therapeutics$460K22.53N/AN/A$10.37 per share0.94ITRMIterum TherapeuticsN/AN/AN/AN/A($0.15) per shareN/AOKUROnKure TherapeuticsN/AN/AN/AN/A$7.78 per shareN/ASNTISenti Biosciences$2.56M14.20N/AN/A$5.31 per share0.26Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateADXNAddex Therapeutics$8.02M-$0.34N/A∞N/A3,584.49%-54.27%-49.15%9/29/2025 (Estimated)ITRMIterum Therapeutics-$24.77M-$0.85N/A∞N/AN/AN/A-65.01%11/13/2025 (Estimated)OKUROnKure Therapeutics-$52.67M-$4.80N/AN/AN/AN/A-60.52%-55.43%11/6/2025 (Estimated)SNTISenti Biosciences-$52.79M-$8.95N/AN/AN/AN/A-223.98%-76.02%11/13/2025 (Estimated)Latest ADXN, OKUR, SNTI, and ITRM EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/12/2025Q2 2025OKUROnKure Therapeutics-$1.23-$1.14+$0.09-$1.14N/AN/A8/7/2025Q2 2025SNTISenti Biosciences-$0.58-$0.56+$0.02-$0.56$1.30 million$0.50 million8/5/2025Q2 2025ITRMIterum Therapeutics-$0.13-$0.16-$0.03-$0.16N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthADXNAddex TherapeuticsN/AN/AN/AN/AN/AITRMIterum TherapeuticsN/AN/AN/AN/AN/AOKUROnKure TherapeuticsN/AN/AN/AN/AN/ASNTISenti BiosciencesN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioADXNAddex TherapeuticsN/A3.023.02ITRMIterum TherapeuticsN/A2.692.52OKUROnKure TherapeuticsN/A11.1311.13SNTISenti BiosciencesN/A3.263.26Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipADXNAddex Therapeutics16.14%ITRMIterum Therapeutics9.21%OKUROnKure Therapeutics90.98%SNTISenti Biosciences25.73%Insider OwnershipCompanyInsider OwnershipADXNAddex Therapeutics15.00%ITRMIterum Therapeutics2.40%OKUROnKure Therapeutics2.30%SNTISenti Biosciences3.12%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableADXNAddex Therapeutics301.06 million901,000Not OptionableITRMIterum Therapeutics1047.17 million46.04 millionNot OptionableOKUROnKure TherapeuticsN/A13.53 million13.22 millionN/ASNTISenti Biosciences426.16 million25.34 millionNot OptionableADXN, OKUR, SNTI, and ITRM HeadlinesRecent News About These CompaniesSenti Bio to Present at the MedInvest Biotech & Pharma ConferenceSeptember 18 at 9:15 AM | globenewswire.comSenti Bio to Present at the H.C. Wainwright 27th Annual Global Investment ConferenceSeptember 2, 2025 | globenewswire.comSenti Biosciences to Present at the Webull Financial Corporate Connect Webinar Series: Biotech/MedTechAugust 14, 2025 | globenewswire.comSenti Biosciences Discusses Phase 2 Dose Selection for SENTI-202 in Virtual Investor SegmentAugust 12, 2025 | quiverquant.comQSenti Bio Participates in Virtual Investor “What This Means” Segment Discussing The Phase 2 Dose and Schedule Selection for SENTI-202 in its Clinical Trial for Acute Myeloid LeukemiaAugust 12, 2025 | globenewswire.comSenti Biosciences, Inc.: Senti Bio Reports Second Quarter 2025 Financial Results and Confirms Next Data Milestone for Phase 1 SENTI-202 Study in Acute Myeloid Leukemia (AML ...August 8, 2025 | finanznachrichten.deSenti Bio Reports Second Quarter 2025 Financial Results and Confirms Next Data Milestone for Phase 1 SENTI-202 Study in Acute Myeloid Leukemia (AML) Expected Q4 2025August 7, 2025 | globenewswire.comSenti Bio Determines Recommended Phase 2 Dose (RP2D) in Phase 1 Study of SENTI-202 for the Treatment of Relapsed/Refractory Hematologic Malignancies, Including Acute Myeloid LeukemiaAugust 5, 2025 | globenewswire.comSenti Biosciences Participates in the Virtual Investor “What’s Your Story” Summer Spotlight On-Demand ConferenceJuly 23, 2025 | finance.yahoo.comSenti Biosciences Participates in the Virtual Investor “What's Your Story” Summer Spotlight On-Demand ConferenceJuly 22, 2025 | globenewswire.comSenti Bio's Chief Medical Officer, Kanya Rajangam, M.D., Ph.D. to Give Feature Presentation at the BioScience ForumJuly 21, 2025 | globenewswire.comSenti Biosciences, Inc. Appoints Bryan Baum to Board of DirectorsJuly 18, 2025 | quiverquant.comQSenti Bio Appoints Entrepreneurial Leader and Investor, Bryan Baum, to Board of DirectorsJuly 18, 2025 | globenewswire.comNASDAQ:SNTI Financials | Senti Biosciences Inc - Investing.comJuly 3, 2025 | investing.comSNTI - Senti Biosciences Inc Sustainability - MorningstarJuly 2, 2025 | morningstar.comMSenti Biosciences CEO Timothy Lu Highlights Advancements in Gene Circuit Technology at Nasdaq’s Amplify Spotlight SeriesJune 30, 2025 | quiverquant.comQSenti Bio Participates in Nasdaq Amplify Spotlight SeriesJune 30, 2025 | globenewswire.comSenti Biosciences, Inc. to Present at 2025 SEED Conference on Tumor-Specific Therapies - NasdaqJune 26, 2025 | nasdaq.comSenti Biosciences, Inc. to Present at 2025 SEED Conference on Tumor-Specific TherapiesJune 24, 2025 | quiverquant.comQSenti Bio to Present at the 2025 Synthetic Biology: Engineering, Evolution, & Design (SEED) ConferenceJune 24, 2025 | globenewswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeADXN, OKUR, SNTI, and ITRM Company DescriptionsAddex Therapeutics NASDAQ:ADXN$9.78 -1.08 (-9.91%) Closing price 09/18/2025 03:57 PM EasternExtended Trading$9.82 +0.05 (+0.51%) As of 09/18/2025 07:34 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Addex Therapeutics Ltd discovers, develops, and commercializes small-molecule pharmaceutical products for central nervous system (CNS) disorders in Switzerland. The company focuses on the discovery of G-protein coupled receptors and enzymes. Its lead programs include Dipraglurant for the treatment of Parkinson's disease levodopa-induced dyskinesia and dystonia, and post-stroke/TBI recovery; ADX71149, a novel orally active metabotropic glutamate receptor subtype 2 positive allosteric modulator (mGlu2 PAM) for the treatment of epilepsy; and GABAB PAM for the treatment of pain, anxiety, overactive bladder, and addiction, as well as substance use disorder. Addex Therapeutics Ltd has license and collaboration agreement with Janssen Pharmaceuticals Inc. for the discovery, development, and commercialization of novel mGlu2 PAM compounds for the treatment of CNS and related diseases; license and research agreement with Indivior PLC discovery, development, and commercialization of novel GABAB PAM compounds for the treatment of addiction and other CNS diseases; and The CharcotMarieTooth Association to evaluate the role of GABAB PAM compounds in preclinical models of CMT1A. The company was formerly known as Addex Pharmaceuticals Ltd. Addex Therapeutics Ltd was founded in 2002 and is based in Geneva, Switzerland.Iterum Therapeutics NASDAQ:ITRM$0.68 +0.01 (+1.42%) Closing price 09/18/2025 04:00 PM EasternExtended Trading$0.68 +0.00 (+0.21%) As of 09/18/2025 07:19 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Iterum Therapeutics plc, a clinical-stage pharmaceutical company, engages in developing and commercializing anti-infectives in Ireland, Bermuda, and the United States. It is developing sulopenem, a novel anti-infective compound with oral and intravenous formulations that is in Phase III clinical trials for the treatment of uncomplicated urinary tract infections, complicated urinary tract infections, and complicated intra-abdominal infections. The company was incorporated in 2015 and is headquartered in Dublin, Ireland.OnKure Therapeutics NASDAQ:OKUR$2.48 +0.09 (+3.77%) Closing price 09/18/2025 04:00 PM EasternExtended Trading$2.52 +0.04 (+1.41%) As of 09/18/2025 07:24 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.OnKure Therapeutics, Inc. engages in discovering and developing precision medicines that target biologically validated drivers of cancers underserved by available therapies. The company uses a structure and computational chemistry driven drug design platform, committed to improving clinical outcomes for patients by building a robust pipeline of small molecule drugs designed to selectively target specific mutations thought to be key drivers of cancer. It is headquartered in Boulder, CO.Senti Biosciences NASDAQ:SNTI$1.39 +0.02 (+1.46%) Closing price 09/18/2025 04:00 PM EasternExtended Trading$1.40 +0.01 (+0.36%) As of 09/18/2025 07:07 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Senti Biosciences, Inc. operates as a preclinical biotechnology company that develops next-generation cell and gene therapies engineered with its gene circuit platform technologies for various diseases. Its lead product candidates utilize allogeneic chimeric antigen receptor natural killer (CAR-NK) cells outfitted with its gene circuit technologies in various oncology indications. The company product candidates include SENTI-202, a Logic Gated OR+NOT off-the-shelf CAR-NK cell therapy designed to target and eliminate cancer cells while sparing the healthy bone marrow; and SENTI-301A for the treatment of hepatocellular carcinoma. It also develops SENTI-401, a Logic Gated off-the-shelf CAR-NK cell therapy designed to target and eliminate colorectal cancer/CRC cells. In addition, the company develops Tumor-Associated Antigen and Protective Antigen Paired Discovery Platform to select and validate NOT GATE antigen candidates and identify tumor-associated antigens in cancer cells. The company has a strategic collaboration with Celest Therapeutics (Shanghai) Co. Ltd for the clinical development of SENTI-301A to treat solid tumors. Senti Biosciences, Inc. was incorporated in 2016 and is headquartered in South San Francisco, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas The Fed Cut Rates: What Now for the S&P 500 and Equity Markets? Eli Lilly’s Oral GLP-1 Breakthrough Could Change Everything Bloom Energy Booms on AI Power Demand and Analyst Upgrades Can Apple’s iPhone 17 and AI Push Its Stock to New Highs? Why Seagate Is Wall Street's New Favorite AI Infrastructure Play New Catalysts Build Positive Pressure on Intel Stock Oracle to Hit $1 Trillion Valuation in 2025: Here’s Why General Mills Is a Generational Opportunity for Income Investors Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
